1: Chem Biodivers. 2007 Aug;4(8):1707-28.

Medicinal chemistry endeavors around the phytocannabinoids.

Stern E, Lambert DM.

Drug Design and Discovery Center and Unité de Chimie pharmaceutique et de
Radiopharmacie, Ecole de Pharmacie, Faculté de Médecine, Université catholique de
Louvain, Avenue E. Mounier 73, U.C.L. 73.40, B-1200 Bruxelles.

Over the past 50 years, a considerable research in medicinal chemistry has been
carried out around the natural constituents of Cannabis sativa L. Following the
identification of Delta9-tetrahydrocannabinol (Delta9-THC) in 1964, critical
chemical modifications, e.g., variation of the side chain at C3 and the opening
of the tricyclic scaffold, have led to the characterization of potent and
cannabinoid receptor subtype-selective ligands. Those ligands that demonstrate
high affinity for the cannabinoid receptors and good biological efficacy are
still used as powerful pharmacological tools. This review summarizes past as well
as recent developments in the structure-activity relationships of
phytocannabinoids.

PMID: 17712816 [PubMed - indexed for MEDLINE]

Related Links

    Recent developments in cannabinoid ligands. [Life Sci. 2005] PMID:15993427

    Structure-activity relationships defining the ACD-tricyclic cannabinoids:
cannabinoid receptor binding and analgesic activity. [Drug Des Discov. 1995]
PMID:8872458

    Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical
cannabinoid agonist interaction. [Biopolymers. 2003] PMID:12767117

    The search for selective ligands for the CB2 receptor. [Curr Pharm Des. 2000]
PMID:10903395

    Behavioral effects of cannabinoid agents in animals. [Crit Rev Neurobiol. 1999]
PMID:10803637